Opinion|Videos|January 12, 2026
Exploring Combination Therapy in Newly Diagnosed cGVHD
Author(s)Leyla O. Shune, MD
Leyla O. Shune, MD, discusses results from an interim safety analysis of a randomized phase 2 study exploring axatilimab in combination with ruxolitinib in patients with newly diagnosed chronic graft-versus-host disease.
Advertisement
Episodes in this series
Leyla O. Shune, MD, discusses results from an interim safety analysis of a randomized phase 2 study exploring axatilimab in combination with ruxolitinib in patients with newly diagnosed chronic graft-versus-host disease. She explains how the results, which were presented at the 2025 ASH Annual Meeting, showed that no new safety signals emerged when combining the 2 agents compared with previously reported outcomes for single-agent use of the treatments.
Advertisement
Related to this article
Financial strain often eases after allogeneic bone marrow transplant, but persistent hardship worsens quality of life, highlighting the need for ongoing support.
Advertisement
Advertisement
Trending on Targeted Onc
1
HT-001 Trial Ended Early, Phase 3 Planned for EGFR Inhibitor Rash Management
2
Zanubrutinib Plus Rituximab Receives FDA Priority Review in Frontline MCL
3
A New Era in Sarcoma Treatment? Dr Banks on the Potential of TIL Therapy
4
Enfortumab Vedotin/Pembrolizumab Cost Effective in Bladder Cancer
5